AutomedicationFrancoV1, Main, Exploration, bibRecord, 001156

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.

Identifieur interne : 001156 ( Main/Exploration ); précédent : 001155; suivant : 001157

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.

Auteurs : P. Fleming [Canada] ; C. Roubille [Canada] ; V. Richer [Canada] ; T. Starnino [Canada] ; C. Mccourt [Canada] ; A. Mcfarlane [Canada] ; S. Siu [Canada] ; J. Kraft [Canada] ; C. Lynde [Canada] ; J E Pope [Canada] ; S. Keeling [Canada] ; J. Dutz [Canada] ; L. Bessette [Canada] ; R. Bissonnette [Canada] ; B. Haraoui [Canada] ; W P Gulliver [Canada]

Source :

Journal of the European Academy of Dermatology and Venereology : JEADV [ 1468-3083 ] ; 2015.

RBID : pubmed:25490866

Descripteurs français

KwdFr :
- Adalimumab (usage thérapeutique), Anti-inflammatoires non stéroïdiens (usage thérapeutique), Dépression (traitement médicamenteux), Dépression (étiologie), Essais contrôlés randomisés comme sujet (MeSH), Humains (MeSH), Produits dermatologiques (usage thérapeutique), Psoriasis (psychologie), Psoriasis (traitement médicamenteux), Ustékinumab (usage thérapeutique), Échelles d'évaluation en psychiatrie (MeSH), Étanercept (usage thérapeutique).
MESH :
- psychologie : Psoriasis.
- traitement médicamenteux : Dépression, Psoriasis.
- usage thérapeutique : Adalimumab, Anti-inflammatoires non stéroïdiens, Produits dermatologiques, Ustékinumab, Étanercept.
- étiologie : Dépression.
- Essais contrôlés randomisés comme sujet, Humains, Échelles d'évaluation en psychiatrie.

English descriptors

KwdEn :
- Adalimumab (therapeutic use), Anti-Inflammatory Agents, Non-Steroidal (therapeutic use), Depression (drug therapy), Depression (etiology), Dermatologic Agents (therapeutic use), Etanercept (therapeutic use), Humans (MeSH), Psoriasis (drug therapy), Psoriasis (psychology), Psychiatric Status Rating Scales (MeSH), Randomized Controlled Trials as Topic (MeSH), Ustekinumab (therapeutic use).
MESH :
- chemical , therapeutic use : Adalimumab, Anti-Inflammatory Agents, Non-Steroidal, Dermatologic Agents, Etanercept, Ustekinumab.
- drug therapy : Depression, Psoriasis.
- etiology : Depression.
- psychology : Psoriasis.
- Humans, Psychiatric Status Rating Scales, Randomized Controlled Trials as Topic.

Abstract

BACKGROUND

Twenty to fifty percent of patients with psoriasis have depressive symptoms.

OBJECTIVE

To describe the effects of biologics (tumour necrosis factor inhibitors [TNFi] or interleukin 12/23 inhibitors [IL-12/23i]) on depressive symptoms in patients with psoriasis.

METHODS

Electronic databases were searched for randomized controlled trials (RCTs) examining the effects of biologics on depressive symptoms in adults with psoriasis.

RESULTS

Of the 305 publications identified, three RCTs were included in a systematic review. In a trial evaluating ustekinumab, mean change in Hospital and Anxiety Depression Rating Scale at 24 weeks from baseline was 3.1 with ustekinumab (P < 0.001) vs. 0.21 with placebo (not significant). In a trial evaluating adalimumab, mean change in Zung Self-Rating Depression Scale at 12 weeks from baseline was -6.7 with adalimumab vs. -1.5 with placebo. In a trial evaluating etanercept, the between-group difference at 12 weeks in Beck Depression Inventory Scale was 1.8 (95% CI: 0.6, 2.90) in favour of etanercept over placebo. Limitations are that diagnostic criteria for depression were not used and scales and data from individual RCTs could not be combined.

CONCLUSION

Adalimumab, etanercept and ustekinumab were associated with statistically significant reductions in depressive symptom scores using various scales in patients with moderate-to-severe psoriasis.

DOI: 10.1111/jdv.12909
PubMed: 25490866

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001155
to stream Main, to step Curation: 001155

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.</title>
<author><name sortKey="Fleming, P" sort="Fleming, P" uniqKey="Fleming P" first="P" last="Fleming">P. Fleming</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Dermatology, University of Toronto, Toronto, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Dermatology, University of Toronto, Toronto, ON</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roubille, C" sort="Roubille, C" uniqKey="Roubille C" first="C" last="Roubille">C. Roubille</name>
<affiliation wicri:level="1"><nlm:affiliation>Notre-Dame Hospital, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Notre-Dame Hospital, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Richer, V" sort="Richer, V" uniqKey="Richer V" first="V" last="Richer">V. Richer</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Dermatology Service, St-Luc Hospital, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Dermatology Service, St-Luc Hospital, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Starnino, T" sort="Starnino, T" uniqKey="Starnino T" first="T" last="Starnino">T. Starnino</name>
<affiliation wicri:level="1"><nlm:affiliation>Sacré-Coeur Hospital of Montreal, University of Montreal, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Sacré-Coeur Hospital of Montreal, University of Montreal, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccourt, C" sort="Mccourt, C" uniqKey="Mccourt C" first="C" last="Mccourt">C. Mccourt</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC</wicri:regionArea>
<orgName type="university">Université de la Colombie-Britannique</orgName>
<placeName><settlement type="city">Vancouver</settlement>
<region type="state">Colombie-Britannique </region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcfarlane, A" sort="Mcfarlane, A" uniqKey="Mcfarlane A" first="A" last="Mcfarlane">A. Mcfarlane</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Rheumatology, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Siu, S" sort="Siu, S" uniqKey="Siu S" first="S" last="Siu">S. Siu</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kraft, J" sort="Kraft, J" uniqKey="Kraft J" first="J" last="Kraft">J. Kraft</name>
<affiliation wicri:level="1"><nlm:affiliation>Lynde Dermatology, Markham, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Lynde Dermatology, Markham, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lynde, C" sort="Lynde, C" uniqKey="Lynde C" first="C" last="Lynde">C. Lynde</name>
<affiliation wicri:level="1"><nlm:affiliation>Lynde Dermatology, Markham, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Lynde Dermatology, Markham, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pope, J E" sort="Pope, J E" uniqKey="Pope J" first="J E" last="Pope">J E Pope</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Keeling, S" sort="Keeling, S" uniqKey="Keeling S" first="S" last="Keeling">S. Keeling</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Rheumatology, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dutz, J" sort="Dutz, J" uniqKey="Dutz J" first="J" last="Dutz">J. Dutz</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC</wicri:regionArea>
<orgName type="university">Université de la Colombie-Britannique</orgName>
<placeName><settlement type="city">Vancouver</settlement>
<region type="state">Colombie-Britannique </region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bessette, L" sort="Bessette, L" uniqKey="Bessette L" first="L" last="Bessette">L. Bessette</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier Universitaire de Québec (pavillon CHUL), Quebec City, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier Universitaire de Québec (pavillon CHUL), Quebec City, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bissonnette, R" sort="Bissonnette, R" uniqKey="Bissonnette R" first="R" last="Bissonnette">R. Bissonnette</name>
<affiliation wicri:level="1"><nlm:affiliation>Innovaderm Research, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Innovaderm Research, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Haraoui, B" sort="Haraoui, B" uniqKey="Haraoui B" first="B" last="Haraoui">B. Haraoui</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM) and Institut de Rhumatologie de Montréal, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM) and Institut de Rhumatologie de Montréal, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gulliver, W P" sort="Gulliver, W P" uniqKey="Gulliver W" first="W P" last="Gulliver">W P Gulliver</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Memorial University of Newfoundland, St. John's, NL</wicri:regionArea>
<wicri:noRegion>NL</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25490866</idno>
<idno type="pmid">25490866</idno>
<idno type="doi">10.1111/jdv.12909</idno>
<idno type="wicri:Area/Main/Corpus">001155</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001155</idno>
<idno type="wicri:Area/Main/Curation">001155</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001155</idno>
<idno type="wicri:Area/Main/Exploration">001155</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.</title>
<author><name sortKey="Fleming, P" sort="Fleming, P" uniqKey="Fleming P" first="P" last="Fleming">P. Fleming</name>
<affiliation wicri:level="4"><nlm:affiliation>Division of Dermatology, University of Toronto, Toronto, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Dermatology, University of Toronto, Toronto, ON</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roubille, C" sort="Roubille, C" uniqKey="Roubille C" first="C" last="Roubille">C. Roubille</name>
<affiliation wicri:level="1"><nlm:affiliation>Notre-Dame Hospital, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Notre-Dame Hospital, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Richer, V" sort="Richer, V" uniqKey="Richer V" first="V" last="Richer">V. Richer</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Dermatology Service, St-Luc Hospital, Montreal, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Dermatology Service, St-Luc Hospital, Montreal</wicri:regionArea>
<placeName><settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Starnino, T" sort="Starnino, T" uniqKey="Starnino T" first="T" last="Starnino">T. Starnino</name>
<affiliation wicri:level="1"><nlm:affiliation>Sacré-Coeur Hospital of Montreal, University of Montreal, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Sacré-Coeur Hospital of Montreal, University of Montreal, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mccourt, C" sort="Mccourt, C" uniqKey="Mccourt C" first="C" last="Mccourt">C. Mccourt</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC</wicri:regionArea>
<orgName type="university">Université de la Colombie-Britannique</orgName>
<placeName><settlement type="city">Vancouver</settlement>
<region type="state">Colombie-Britannique </region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcfarlane, A" sort="Mcfarlane, A" uniqKey="Mcfarlane A" first="A" last="Mcfarlane">A. Mcfarlane</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Rheumatology, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Siu, S" sort="Siu, S" uniqKey="Siu S" first="S" last="Siu">S. Siu</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kraft, J" sort="Kraft, J" uniqKey="Kraft J" first="J" last="Kraft">J. Kraft</name>
<affiliation wicri:level="1"><nlm:affiliation>Lynde Dermatology, Markham, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Lynde Dermatology, Markham, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lynde, C" sort="Lynde, C" uniqKey="Lynde C" first="C" last="Lynde">C. Lynde</name>
<affiliation wicri:level="1"><nlm:affiliation>Lynde Dermatology, Markham, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Lynde Dermatology, Markham, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pope, J E" sort="Pope, J E" uniqKey="Pope J" first="J E" last="Pope">J E Pope</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON</wicri:regionArea>
<wicri:noRegion>ON</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Keeling, S" sort="Keeling, S" uniqKey="Keeling S" first="S" last="Keeling">S. Keeling</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Rheumatology, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Rheumatology, University of Alberta, Edmonton, AB</wicri:regionArea>
<wicri:noRegion>AB</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Dutz, J" sort="Dutz, J" uniqKey="Dutz J" first="J" last="Dutz">J. Dutz</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC</wicri:regionArea>
<orgName type="university">Université de la Colombie-Britannique</orgName>
<placeName><settlement type="city">Vancouver</settlement>
<region type="state">Colombie-Britannique </region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bessette, L" sort="Bessette, L" uniqKey="Bessette L" first="L" last="Bessette">L. Bessette</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier Universitaire de Québec (pavillon CHUL), Quebec City, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier Universitaire de Québec (pavillon CHUL), Quebec City, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bissonnette, R" sort="Bissonnette, R" uniqKey="Bissonnette R" first="R" last="Bissonnette">R. Bissonnette</name>
<affiliation wicri:level="1"><nlm:affiliation>Innovaderm Research, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Innovaderm Research, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Haraoui, B" sort="Haraoui, B" uniqKey="Haraoui B" first="B" last="Haraoui">B. Haraoui</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM) and Institut de Rhumatologie de Montréal, Montreal, QC, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM) and Institut de Rhumatologie de Montréal, Montreal, QC</wicri:regionArea>
<wicri:noRegion>QC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gulliver, W P" sort="Gulliver, W P" uniqKey="Gulliver W" first="W P" last="Gulliver">W P Gulliver</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Memorial University of Newfoundland, St. John's, NL</wicri:regionArea>
<wicri:noRegion>NL</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of the European Academy of Dermatology and Venereology : JEADV</title>
<idno type="eISSN">1468-3083</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab (therapeutic use)</term>
<term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term>
<term>Depression (drug therapy)</term>
<term>Depression (etiology)</term>
<term>Dermatologic Agents (therapeutic use)</term>
<term>Etanercept (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Psoriasis (drug therapy)</term>
<term>Psoriasis (psychology)</term>
<term>Psychiatric Status Rating Scales (MeSH)</term>
<term>Randomized Controlled Trials as Topic (MeSH)</term>
<term>Ustekinumab (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adalimumab (usage thérapeutique)</term>
<term>Anti-inflammatoires non stéroïdiens (usage thérapeutique)</term>
<term>Dépression (traitement médicamenteux)</term>
<term>Dépression (étiologie)</term>
<term>Essais contrôlés randomisés comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Produits dermatologiques (usage thérapeutique)</term>
<term>Psoriasis (psychologie)</term>
<term>Psoriasis (traitement médicamenteux)</term>
<term>Ustékinumab (usage thérapeutique)</term>
<term>Échelles d'évaluation en psychiatrie (MeSH)</term>
<term>Étanercept (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adalimumab</term>
<term>Anti-Inflammatory Agents, Non-Steroidal</term>
<term>Dermatologic Agents</term>
<term>Etanercept</term>
<term>Ustekinumab</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depression</term>
<term>Psoriasis</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Psoriasis</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Psoriasis</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dépression</term>
<term>Psoriasis</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adalimumab</term>
<term>Anti-inflammatoires non stéroïdiens</term>
<term>Produits dermatologiques</term>
<term>Ustékinumab</term>
<term>Étanercept</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Dépression</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Psychiatric Status Rating Scales</term>
<term>Randomized Controlled Trials as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term>
<term>Humains</term>
<term>Échelles d'évaluation en psychiatrie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Twenty to fifty percent of patients with psoriasis have depressive symptoms.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b>
</p>
<p>To describe the effects of biologics (tumour necrosis factor inhibitors [TNFi] or interleukin 12/23 inhibitors [IL-12/23i]) on depressive symptoms in patients with psoriasis.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>Electronic databases were searched for randomized controlled trials (RCTs) examining the effects of biologics on depressive symptoms in adults with psoriasis.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Of the 305 publications identified, three RCTs were included in a systematic review. In a trial evaluating ustekinumab, mean change in Hospital and Anxiety Depression Rating Scale at 24 weeks from baseline was 3.1 with ustekinumab (P < 0.001) vs. 0.21 with placebo (not significant). In a trial evaluating adalimumab, mean change in Zung Self-Rating Depression Scale at 12 weeks from baseline was -6.7 with adalimumab vs. -1.5 with placebo. In a trial evaluating etanercept, the between-group difference at 12 weeks in Beck Depression Inventory Scale was 1.8 (95% CI: 0.6, 2.90) in favour of etanercept over placebo. Limitations are that diagnostic criteria for depression were not used and scales and data from individual RCTs could not be combined.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Adalimumab, etanercept and ustekinumab were associated with statistically significant reductions in depressive symptom scores using various scales in patients with moderate-to-severe psoriasis.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25490866</PMID>
<DateCompleted><Year>2016</Year>
<Month>03</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-3083</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>29</Volume>
<Issue>6</Issue>
<PubDate><Year>2015</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Journal of the European Academy of Dermatology and Venereology : JEADV</Title>
<ISOAbbreviation>J Eur Acad Dermatol Venereol</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.</ArticleTitle>
<Pagination><MedlinePgn>1063-70</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/jdv.12909</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Twenty to fifty percent of patients with psoriasis have depressive symptoms.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the effects of biologics (tumour necrosis factor inhibitors [TNFi] or interleukin 12/23 inhibitors [IL-12/23i]) on depressive symptoms in patients with psoriasis.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Electronic databases were searched for randomized controlled trials (RCTs) examining the effects of biologics on depressive symptoms in adults with psoriasis.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 305 publications identified, three RCTs were included in a systematic review. In a trial evaluating ustekinumab, mean change in Hospital and Anxiety Depression Rating Scale at 24 weeks from baseline was 3.1 with ustekinumab (P < 0.001) vs. 0.21 with placebo (not significant). In a trial evaluating adalimumab, mean change in Zung Self-Rating Depression Scale at 12 weeks from baseline was -6.7 with adalimumab vs. -1.5 with placebo. In a trial evaluating etanercept, the between-group difference at 12 weeks in Beck Depression Inventory Scale was 1.8 (95% CI: 0.6, 2.90) in favour of etanercept over placebo. Limitations are that diagnostic criteria for depression were not used and scales and data from individual RCTs could not be combined.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Adalimumab, etanercept and ustekinumab were associated with statistically significant reductions in depressive symptom scores using various scales in patients with moderate-to-severe psoriasis.</AbstractText>
<CopyrightInformation>© 2014 European Academy of Dermatology and Venereology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleming</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Division of Dermatology, University of Toronto, Toronto, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Roubille</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Notre-Dame Hospital, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Richer</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Dermatology Service, St-Luc Hospital, Montreal, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Starnino</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Sacré-Coeur Hospital of Montreal, University of Montreal, Montreal, QC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McCourt</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>McFarlane</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Rheumatology, University of Alberta, Edmonton, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Siu</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kraft</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Lynde Dermatology, Markham, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lynde</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Lynde Dermatology, Markham, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pope</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, Western University, St. Joseph's Health Care, London, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Keeling</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Rheumatology, University of Alberta, Edmonton, AB, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dutz</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bessette</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier Universitaire de Québec (pavillon CHUL), Quebec City, QC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bissonnette</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Innovaderm Research, Montreal, QC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Haraoui</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM) and Institut de Rhumatologie de Montréal, Montreal, QC, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gulliver</LastName>
<ForeName>W P</ForeName>
<Initials>WP</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
<PublicationType UI="D000078182">Systematic Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>12</Month>
<Day>10</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>J Eur Acad Dermatol Venereol</MedlineTA>
<NlmUniqueID>9216037</NlmUniqueID>
<ISSNLinking>0926-9959</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003879">Dermatologic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>FU77B4U5Z0</RegistryNumber>
<NameOfSubstance UI="D000069549">Ustekinumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>FYS6T7F842</RegistryNumber>
<NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OP401G7OJC</RegistryNumber>
<NameOfSubstance UI="D000068800">Etanercept</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003879" MajorTopicYN="N">Dermatologic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068800" MajorTopicYN="N">Etanercept</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011565" MajorTopicYN="N">Psoriasis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000069549" MajorTopicYN="N">Ustekinumab</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>09</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>11</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>12</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>12</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>3</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25490866</ArticleId>
<ArticleId IdType="doi">10.1111/jdv.12909</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Colombie-Britannique </li>
<li>Ontario</li>
<li>Québec</li>
</region>
<settlement><li>Montréal</li>
<li>Toronto</li>
<li>Vancouver</li>
</settlement>
<orgName><li>Université de Toronto</li>
<li>Université de la Colombie-Britannique</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Fleming, P" sort="Fleming, P" uniqKey="Fleming P" first="P" last="Fleming">P. Fleming</name>
</region>
<name sortKey="Bessette, L" sort="Bessette, L" uniqKey="Bessette L" first="L" last="Bessette">L. Bessette</name>
<name sortKey="Bissonnette, R" sort="Bissonnette, R" uniqKey="Bissonnette R" first="R" last="Bissonnette">R. Bissonnette</name>
<name sortKey="Dutz, J" sort="Dutz, J" uniqKey="Dutz J" first="J" last="Dutz">J. Dutz</name>
<name sortKey="Gulliver, W P" sort="Gulliver, W P" uniqKey="Gulliver W" first="W P" last="Gulliver">W P Gulliver</name>
<name sortKey="Haraoui, B" sort="Haraoui, B" uniqKey="Haraoui B" first="B" last="Haraoui">B. Haraoui</name>
<name sortKey="Keeling, S" sort="Keeling, S" uniqKey="Keeling S" first="S" last="Keeling">S. Keeling</name>
<name sortKey="Kraft, J" sort="Kraft, J" uniqKey="Kraft J" first="J" last="Kraft">J. Kraft</name>
<name sortKey="Lynde, C" sort="Lynde, C" uniqKey="Lynde C" first="C" last="Lynde">C. Lynde</name>
<name sortKey="Mccourt, C" sort="Mccourt, C" uniqKey="Mccourt C" first="C" last="Mccourt">C. Mccourt</name>
<name sortKey="Mcfarlane, A" sort="Mcfarlane, A" uniqKey="Mcfarlane A" first="A" last="Mcfarlane">A. Mcfarlane</name>
<name sortKey="Pope, J E" sort="Pope, J E" uniqKey="Pope J" first="J E" last="Pope">J E Pope</name>
<name sortKey="Richer, V" sort="Richer, V" uniqKey="Richer V" first="V" last="Richer">V. Richer</name>
<name sortKey="Roubille, C" sort="Roubille, C" uniqKey="Roubille C" first="C" last="Roubille">C. Roubille</name>
<name sortKey="Siu, S" sort="Siu, S" uniqKey="Siu S" first="S" last="Siu">S. Siu</name>
<name sortKey="Starnino, T" sort="Starnino, T" uniqKey="Starnino T" first="T" last="Starnino">T. Starnino</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001156 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001156 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    AutomedicationFrancoV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25490866
   |texte=   Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25490866" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AutomedicationFrancoV1

This area was generated with Dilib version V0.6.38.
Data generation: Mon Mar 15 15:24:36 2021. Site generation: Mon Mar 15 15:32:03 2021

	Serveur d'exploration sur l'automédication dans le monde francophone
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'automédication dans le monde francophone

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki